Olink Holding Ab (Publ) Stock Price, News & Analysis

Olink Holding AB (Nasdaq: OLK) announced the launch of the Olink® Signature Q100, a benchtop system designed for multiplex protein biomarker measurement. This innovation allows researchers to measure up to 92 proteins simultaneously using only one microliter of plasma or serum, enhancing access to high-quality proteomics data. The Signature Q100 has been positively received during beta testing at six customer labs, demonstrating effective performance. Olink aims to broaden its application-focused solutions and support biomarker research needs.

Psomagen partners with Olink to enhance multi-omics clinical studies using innovative DNA-coupled immunoassay technology. This collaboration aims to streamline drug development by enabling comprehensive protein biomarker analysis in clinical samples. Leveraging Psomagen's 17 years of genomic sequencing expertise and Olink’s Proximity Extension Assay technology, the partnership seeks to significantly improve research efficiency and contribute to the development of precision therapies. The integration of Olink's assays will complement Psomagen’s existing services, enhancing their position as a leading integrative omics solutions provider.

Olink Holding AB (publ) reported Q3 2021 revenue of $20.0 million, an 82% increase year-over-year. For the first nine months, revenues reached $51.3 million, marking a 91% growth. Adjusted EBITDA was (7.9) million, compared to $2.9 million last year, with a net loss of (5.5) million, versus (0.1) million in Q3 2020. Olink anticipates full-year revenues between $90 million and $92 million. The Explore Kit, comprising 63% of Q3 revenues, contributed significantly despite supply chain hurdles.

Olink Holding AB (Nasdaq: OLK) has announced participation in two key investor events in November 2021. The first is a virtual investor day on November 15, featuring discussions with leading experts on ongoing research projects and Olink's commercial strategy. The second event is the Nordic Post IPO Seminar 2021, where CFO Oskar Hjelm will present on November 24. Olink aims to advance proteomics through its collaborations in academia and biopharma, enhancing understanding of human biology and contributing to modern healthcare solutions.

Fulgent Genetics and Olink Proteomics have launched a strategic partnership to enhance biomarker research and clinical trials. Through this collaboration, Fulgent will provide Olink assays via its CLIA-certified labs in California and China, creating a comprehensive multi-omics platform.

This integration allows researchers to access a broad test menu, including genomics and proteomics, from one portal, streamlining workflows and improving efficiency. The partnership aims to simplify clinical trials for pharmaceutical customers.

Olink Holding AB (Nasdaq: OLK) will announce its third quarter 2021 financial results on November 10, 2021, before market opening. A conference call with management will follow at 8:00 a.m. ET. Interested investors can join the call by dialing provided numbers or through a live webcast. Olink is recognized for its proteomics platform, catering to biopharmaceutical firms and research institutions to enhance healthcare and biological understanding. Founded in 2016, the company is headquartered in Uppsala, Sweden.

Olink Holding AB (Nasdaq: OLK) announced participation in two major virtual investor conferences. CEO Jon Heimer and CFO Oskar Hjelm will be featured in a fireside chat at the Goldman Sachs Eighteenth Annual European Medtech and Healthcare Services Conference on September 8 at 10:30 a.m. ET, followed by a discussion at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10 at 8:00 a.m. ET. Live and archived webcasts of these events will be accessible on the company’s investor relations website.

Olink Proteomics AB (ticker: OLK) has announced a strategic collaboration with CellCarta to enhance targeted protein biomarker quantification for clinical studies. This partnership enables CellCarta to utilize Olink's Proximity Extension Assay technology through its Q100 instruments, making it the first global clinical CRO to offer this advanced proteomic capability. The collaboration aims to address the demand for proteomic biomarkers, supporting multi-omic analysis in clinical trials. The integration of Olink's technology promises improved sensitivity and specificity in protein detection, crucial for advancements in therapeutic development.

Olink Holding AB (Nasdaq: OLK) reported strong second quarter 2021 results, with revenue reaching $17.7 million, a 124% year-over-year growth. The net loss was ($10.6 million), compared to ($2.0 million) in Q2 2020. Adjusted EBITDA was (6.3 million), worsening from (1.3 million) the previous year. Olink anticipates full-year revenue between $90 million and $92 million. The company highlighted success in its Explore platform, generating 53% of total revenue, signaling positive market adoption.